Activation of complement pathways after contusion-induced spinal cord injury

Journal of Neurotrauma

Volumn 21, Issue 12, 2004, Pages 1831-1846

  Anderson, Aileen J ^a   Robert, Stephanie ^a   Huang, Wencheng ^b   Young, Wise ^b   Cotman, Carl W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

Complement cascade; Demyelination; Immune response; Inflammation; Neurodegeneration; Neuron; Oligodendrocyte

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C5B; COMPLEMENT COMPONENT C9;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL TYPE; CELLULAR IMMUNITY; COMPLEMENT ACTIVATION; COMPLEMENT CLASSICAL PATHWAY; CONTROLLED STUDY; CONTUSION; DEMYELINATION; IMMUNE RESPONSE; IMMUNOREACTIVITY; INFLAMMATION; MACROGLIA; NERVE FIBER DEGENERATION; NONHUMAN; RAT; SPINAL CORD INJURY;

ANIMALS; CELL COUNT; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; NEUROGLIA; NEURONS; RATS; RATS, LONG-EVANS; SPINAL CORD INJURIES; TIME FACTORS; TRAUMA SEVERITY INDICES;

EID: 9744246880     PISSN: 08977151     EISSN: None     Source Type: Journal    
DOI: 10.1089/neu.2004.21.1831     Document Type: Article

References (99)

1. AGOROPOULOU, C., PIDDLESDEN, S.J., LACHMANN, P.J., and WING, M.G. (1998). Neuronal protection of oligodendrocytes from antibody-independent complement lysis. Neuroreport 9, 927-932.
2. AGOROPOULOU, C., WING, M.G., and WOOD, A. (1996). CD59 expression and complement susceptibility of human neuronal cell line (NTera2). Neuroreport 7, 997-1004.
3. ANDERSON, A.J., SU, J.H., and COTMAN, C.W. (1996). DNA damage and apoptosis in Alzheimer's disease: colocalization with c-Jun immunoreactivity, relationship to brain area, and effect of postmortem delay. J. Neurosci. 16, 1710-1719.
4. BARNUM, S.R. (1999). Inhibition of complement as a therapeutic approach in inflammatory central nervous system (CNS) disease. Mol. Med. 5, 569-582.
5. BARTHOLDI, D., and SCHWAB, M.E. (1995). Methylprednisolone inhibits early inflammatory processes but not ischemic cell death after experimental spinal cord lesion in the rat. Brain Res. 672, 177-186.
6. BARTHOLDI, D., and SCHWAB, M.E. (1997). Expression of pro-inflammatory cytokine and chemokine mRNA upon experimental spinal cord injury in mouse: an in situ hybridization study. Eur. J. Neurosci. 9, 1422-1438.
7. BAVETTA, S., HAMLYN, P.J., BURNSTOCK, G., LIEBERMAN, A.R., and ANDERSON, P.N. (1999). The effects of FK506 on dorsal column axons following spinal cord injury in adult rats: neuroprotection and local regeneration. Exp. Neurol. 158, 382-393.
8. BELLANDER, B.M., VON HOLST, H., FREDMAN, P., and SVENSSON, M. (1996). Activation of the complement cascade and increase of clusterin in the brain following a cortical contusion in the adult rat. J. Neurosurg. 85, 468-475.
9. BETHEA, J.R., NAGASHIMA, H., ACOSTA, M.C., et al. (1999). Systemically administered interleukin-10 reduces tumor necrosis factor-alpha production and significantly improves functional recovery following traumatic spinal cord injury in rats. J. Neurotrauma 16, 851-863.
10. BHAT, R.V., AXT, K.J., FOSNAUGH, J.S., et al. (1996). Expression of the APC tumor suppressor protein in oligodendroglia. Glia 17, 169-174.
11. BIRDSALL, H.H., GREEN D.M., TRIAL J., et al. (1997). Complement C5a, TGF-beta 1, and MCP-1, in sequence, induce migration of monocytes into ischemic canine myocardium within the first one to five hours after reperfusion. Circulation 95, 684-692.
12. BLIGHT, A.R. (1994). Effects of silica on the outcome from experimental spinal cord injury: implication of macrophages in secondary tissue damage. Neuroscience 60, 263-273.
13. BRACKEN, M.B., ALDRICH, E.F., HERR, D.L., et al. (2000). Clinical measurement, statistical analysis, and risk-benefit: controversies from trials of spinal injury. J. Trauma 48, 558-561.
14. BREWER, K.L., BETHEA, J.R., and YEZIERSKI, R.P. (1999). Neuroprotective effects of interleukin-10 following excitotoxic spinal cord injury. Exp. Neurol. 159, 484-493.
15. BRÜCK, W., BRÜCK, Y., DIEDERICH, U., and PIDDLESDEN, S.J. (1995). The membrane attack complex of complement mediates peripheral nervous system demyelination in vitro. Acta Neuropathol. (Berl.) 90, 601-607.
16. BRÜCK, W., and FRIEDE, R.L. (1990). Anti-macrophage CR3 antibody blocks myelin phagocytosis by macrophages in vitro. Acta Neuropathol. (Berl.) 80, 415-418.
17. CARLSON, S.L., PARRISH, M.E., SPRINGER, J.E., DOTY, K., and DOSSETT, L. (1998). Acute inflammatory response in spinal cord following impact injury. Exp. Neurol. 151, 77-88.
18. CHEN, A., XU, X.M., KLEITMAN, N., and BUNGE, M.B. (1996). Methylprednisolone administration improves axonal regeneration into Schwann cell grafts in transected adult rat thoracic spinal cord. Exp. Neurol. 138, 261-276.
19. CONSTANTINI, S., and YOUNG, W. (1994). The effects of methylprednisolone and the ganglioside GM1 on acute spinal cord injury in rats. J. Neurosurg. 80, 97-111.
20. DAILEY, A.T., AVELLINO, A.M., BENTHEM, L., SILVER, J., and KLIOT, M. (1998). Complement depletion reduces macrophage infiltration and activation during Wallerian degeneration and axonal regeneration. J. Neurosci. 18, 6713-6722.
21. DASHIELL, S.M., and KOSKI, C.L. (1999). Sublytic terminal complement complexes decrease P0 Gene expression in Schwann cells. J. Neurochem. 73, 2321-2330.
22. DASHIELL, S.M., RUS, H., and KOSKI, C.L. (2000). Terminal complement complexes concomitantly stimulate proliferation and rescue of Schwann cells from apoptosis. Glia 30, 187-198.
23. DAVOUST, N., NATAF, S., REIMAN, R., HOLERS, M.V., CAMPBELL, I.L., and BARNUM, S.R. (1999). Central nervous system-targeted expression of the complement inhibitor sCrry prevents experimental allergic encephalomyelitis. J. Immunol. 163, 6551-6556.
24. DEJONG, B.A., and SMITH, M.E. (1997). A role for complement in phagocytosis of myelin. Neurochem. Res. 22, 491-498.
25. DUSART, I., and SCHWAB, M.E. (1994). Secondary cell death and the inflammatory reaction after dorsal hemisection of the rat spinal cord. Eur. J. Neurosci. 6, 712-724.
26. DYER, J.K., BOURQUE, J.A., and STEEVES, J.D. (1998). Regeneration of brainstem-spinal axons after lesion and immunological disruption of myelin in adult rat. Exp. Neurol. 154, 12-22.
27. EGGLETON, P., REID, K.B., and TENNER, A.J. (1998). C1q-how many functions? How many receptors? Trends Cell Biol. 8, 428-431.
28. EIKELENBOOM, P., and VEERHUIS, R. (1996). The role of complement and activated microglia in the pathogenesis of Alzheimer's disease. Neurobiol. Aging 17, 673-680.
29. FARKAS, I., BARANYI, L., LIPOSITS, Z.S., YAMAMOTO, T., and OKADA, H. (1998a). Complement C5a anaphylatoxin fragment causes apoptosis in TGW neuroblastoma cells. Neuroscience 86, 903-911.
30. FARKAS, I., BARANYI, L., TAKAHASHI, M., et al. (1998b). A neuronal C5a receptor and an associated apoptotic signal transduction pathway. J. Physiol. (Lond). 507, 679-687.
31. FERRARI, S., MORBIN, M., NOBILE-ORAZIO, E., et al. (1998). Antisulfatide polyneuropathy: antibody-mediated complement attack on peripheral myelin. Acta Neuropathol. (Berl.) 96, 569-574.
32. CASQUE, P., FONTAINE, M., and MORGAN, B.P. (1995). Complement expression in human brain. Biosynthesis of terminal pathway components and regulators in human glial cells and cell lines. J. Immunol. 154, 4726-4733.
33. GHIRNIKAR, R.S., LEE, Y.L., and ENG, L.F. (2000). Chemokine antagonist infusion attenuates cellular infiltration following spinal cord contusion injury in rat. J. Neurosci. Res. 59, 63-73.
34. GIULIAN, D., and ROBERTSON, C. (1990). Inhibition of mononuclear phagocytes reduces ischemic injury in the spinal cord. Ann. Neurol. 27, 33-42.
35. GUTHRIE, K.M., ANDERSON, A.J., LEON, M., and GALL, C.M. (1993). Odor-induced increases in c-fos mRNA reveal an anatomical "unit" for odor processing in olfactory bulb. Proc. Natl. Acad. Sci. USA 90, 3329-3333.
36. HAUBEN, E., AGRANOV, E., GOTHILF, A., et al. (2001). Posttraumatic therapeutic vaccination with modified myelin self-antigen prevents complete paralysis while avoiding autoimmune disease. J. Clin. Invest. 108, 591-599.
37. HAUBEN, E., IBARRA, A., MIZRAHI, T., BAROUCH, R., AGRANOV, E., and SCHWARTZ, M. (2001). Vaccination with a Nogo-A-derived peptide after incomplete spinal-cord injury promotes recovery via a T-cell-mediated neuroprotective response: comparison with other myelin antigens. Proc. Natl. Acad. Sci. USA 98, 15173-15178.
38. HAUBEN, E., NEVO, U., YOLES, E., et al. (2000). Autoimmune T cells as potential neuroprotective therapy for spinal cord injury. Lancet 355, 286-287.
39. HICKS, R.R., KEELING, K.L., YANG, M.Y., SMITH, S.A., SIMONS, A.M., and KOTWAL, G.J. (2002). Vaccinia virus complement control protein enhances functional recovery after traumatic brain injury. J. Neurotrauma 19, 705-714.
40. HUANG, J., KIM, L.J., MEALEY, R., et al. (1999). Neuronal protection in stroke by an sLex-glycosylated complement inhibitory protein. Science 285, 595-599.
41. ITAGAKI, S., AKIYAMA, H., SAITO, H., and MCGEER, P.L. (1994). Ultrastructural localization of complement membrane attack complex (MAC)-like immunoreactivity in brains of patients with Alzheimer's disease. Brain Res. 645, 78-84.
42. JOHNS, T.G., and BERNARD, C.C. (1997). Binding of complement component C1q to myelin oligodendrocyte glycoprotein: a novel mechanism for regulating CNS inflammation. Mol. Immunol. 34, 33-38.
43. JOHNSON, S., YOUNG-CHAN, C.S., LAPING, N.J., and FINCH, C.E. (1996). Perforant path transection induces complement C9 deposition in hippocampus. Exp. Neurol. 138, 198-205.
44. JUNG, S., TOYKA, K.V., and HARTUNG, H.P. (1995). Soluble complement receptor type 1 inhibits experimental autoimmune neuritis in Lewis rats. Neurosci. Lett. 200, 167-170.
45. KANELLOPOULOS, G.K., KATO, H., WU, Y., et al. (1997). Neuronal cell death in the ischemic spinal cord: the effect of methylprednisolone. Ann. Thorac. Surg. 64, 1279-1285; discussion 1286.
46. KEIRSTEAD, H.S., HUGHES, H.C., and BLAKEMORE, W.F. (1998). A quantifiable model of axonal regeneration in the demyelinated adult rat spinal cord. Exp. Neurol. 151, 303-313.
47. KOSSMANN, T., STAHEL, P.P., MORGANTI-KOSSMANN, M.C., JONES, J.L., and BARNUM, S.R. (1997). Elevated levels of the complement components C3 and factor B in ventricular cerebrospinal fluid of patients with traumatic brain injury. J. Neuroimmunol. 73, 63-69.
48. LINDSBERG, P.J., OHMAN, J., LEHTO, T., et al. (1996). Complement activation in the central nervous system following blood-brain barrier damage in man. Ann. Neurol. 40, 587-596.
49. LIU, L., PERSSON, J.K., SVENSSON, M., and ALDSKOGIUS, H. (1998). Glial cell responses, complement, and clusterin in the central nervous system following dorsal root transection. Glia 23, 221-238.
50. LIU, L., TÖRNQVIST, E., MATTSSON, P., et al. (1995). Complement and clusterin in the spinal cord dorsal horn and gracile nucleus following sciatic nerve injury in the adult rat. Neuroscience 68, 167-179.
51. MAKRIDES, S.C. (1998). Therapeutic inhibition of the complement system. Pharmacol. Rev. 50, 59-87.
52. MEAD, R.J., SINGHRAO, S.K., NEAL, J.W., LASSMANN, H., and MORGAN, B.P. (2002). The membrane attack complex of complement causes severe demyelination associated with acute axonal injury. J. Immunol. 168, 458-465.
53. MORGAN, B.P. (1989). Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects. Biochem. J. 264, 1-14.
54. MORGAN, B.P. (1995). Physiology and pathophysiology of complement: Progress and trends. Crit. Rev. Clin. Lab. Sci. 32, 265-298.
55. MOSLEY, K., and CUZNER, M.L. (1996). Receptor-mediated phagocytosis of myelin by macrophages and microglia: effect of opsonization and receptor blocking agents. Neurochem. Res. 21, 481-487.
56. NASO, W.B., PEROT, P.L., JR., and COX, R.D. (1995). The neuroprotective effect of high-dose methylprednisolone in rat spinal cord hemisection. Neurosci. Lett. 189, 176-178.
57. NESIC, O., XU, G.Y., MCADOO, D., HIGH, K.W., HULSE-BOSCH, C., and PEREZ-POL, R. (2001). IL-I receptor antagonist prevents apoptosis and caspase-3 activation after spinal cord injury. J. Neurotrauma 18, 947-956.
58. NOBLE, L.J., and WRATHALL, J.R. (1989). Distribution and time course of protein extravasation in the rat spinal cord after contusive injury. Brain Res. 482, 57-66.
59. OLBY, N.J., and BLAKEMORE, W.F. (1996). A new method of quantifying the extent of tissue loss following spinal cord injury in the rat. Exp. Neurol. 138, 82-92.
60. OUDEGA, M., VARGAS, C.G., WEBER, A.B., KLEITMAN, N., and BUNGE, M.B. (1999). Long-term effects of methylprednisolone following transection of adult rat spinal cord. Eur. J. Neurosci. 11, 2453-2464.
61. PAN, W., BANKS, W.A., and KASTIN, A.J. (1997a). Blood-brain barrier permeability to ebiratide and TNF in acute spinal cord injury. Exp. Neurol. 146, 367-373.
62. PAN, W., BANKS, W.A., and KASTIN, A.J. (1997b). Permeability of the blood-brain and blood-spinal cord barriers to interferons. J. Neuroimmunol. 76, 105-111.
63. PASINETTI, G.M., JOHNSON, S.A., ROZOVSKY, M., et al. (1992). Complement C1qB and C4 mRNA responses to leisoning in rat brain. Exp. Neurol. 118, 117-125.
64. PIDDLESDEN, S.J., JIANG, S., LEVIN, J.L., VINCENT, A., and MORGAN, B.P. (1996). Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis. J. Neuroimmunol. 71, 173-177.
65. PIDDLESDEN, S.J., STORCH, M.K., HIBBS, M., FREEMAN, A.M., LASSMANN, H., and MORGAN, B.P. (1994). Soluble recombinant complement receptor 1 inhibits inflammation and demyelination in antibody-mediated demyelinating experimental allergic encephalomyelitis. J. Immunol. 152, 5477-5484.
66. POPOVICH, P.O., GUAN, Z., WEI, P., HUITINGA, I., VAN ROOIJEN, N., and STOKES, B.T. (1999). Depletion of hematogenous macrophages promotes partial hindlimb recovery and neuroanatomical repair after experimental spinal cord injury. Exp. Neurol. 158, 351-365.
67. POPOVICH, P.C., HORNER, P.J., MULLIN, B.B., and STOKES, B.T. (1996). A quantitative spatial analysis of the blood-spinal cord barrier. I. Permeability changes after experimental spinal contusion injury. Exp. Neurol. 142, 258-275.
68. POPOVICH, P.C., WEI, P., and STOKES, B.T. (1997). Cellular inflammatory response after spinal cord injury in Sprague-Dawley and Lewis rats. J. Comp. Neurol. 377, 443-464.
69. RABCHEVSKY, A.G., FUGACCIA, I., SULLIVAN, P.C., BLADES, D.A., and SCHEFF, S.W. (2002). Efficacy of methylprednisolone therapy for the injured rat spinal cord. J. Neurosci. Res. 68, 7-18.
70. RANCAN, M., MORGANTI-KOSSMANN, M.C., BARNUM, S.R., et al. (2003). Central nervous system-targeted complement inhibition mediates neuroprotection after closed head injury in transgenic mice. J. Cereb. Blood Flow Metab. 23, 1070-1074.
71. RAPALINO, O., LAZAROV-SPIEGLER, O., AGRANOV, E., et al. (1998). Implantation of stimulated homologous macrophages results in partial recovery of paraplegic rats. Nat. Med. 4, 814-821.
72. ROZOVSKY, I., MORGAN, T.E., WILLOUGHBY, D.A., et al. (1994). Selective expression of clusterin (SGP-2), and complement C1qB and C4 during responses to neurotoxins in vivo and in vitro. Neuroscience 62, 741-758.
73. RUS, H.G., NICULESCU, F., and SHIN, M.L. (1996). Sublytic complement attack induces cell cycle in oligodendrocytes. J. Immunol. 156, 4892-4900.
74. SAIJA, A., PRINCI, P., LANZA, M., SCALESE, M., ARAMNEJAD, E., and DE SARRO, A. (1995). Systemic cytokine administration can affect blood-brain barrier permeability in the rat. Life Sci. 56, 775-784.
75. SCHWARTZ, M., and HAUBEN, E. (2002). Differing views on spinal cord repair. Science 296, 1400; author reply 1400.
76. SCOLDING, N.J., HOUSTON, W.A., MORGAN, B.P., CAMPBELL, A.K., and COMPSTON, D.A. (1989). Reversible injury of cultured rat oligodendrocytes by complement. Immunology 67, 441-446.
77. SCOLDING, N.J., MORGAN, B.P., HOUSTON, A., CAMPBELL, A.K., LININGTON, C., and COMPSTON, D.A. (1989). Normal rat serum cytotoxicity against syngenetic oligodendrocytes: complement activation and attack in the absence of anti-myelin antibodies. J. Neurol. Sci. 89, 289-300.
78. SHEN, Y., HALPERIN, J.A., BENZAQUEN, L., and LEE, C.M. (1997). Characterization of neuronal cell death induced by complement activation. Brain Res. Brain Res. Protoc. 1, 186-194.
79. SHEN, Y., HALPERIN, J.A., and LEE, C.M. (1995). Complement-mediated neurotoxicity is regulated by homologous restriction. Brain Res. 671, 282-292.
80. SHIRAZI, Y., RUS, H.G., MACKLIN, W.B., and SHIN, M.L. (1993). Enhanced degradation of messenger RNA encoding myelin proteins by terminal complement complexes in oligodendrocytes. J. Immunol. 150, 4581-4590.
81. SINGHRAO, S.K., NEAL, J.W., MORGAN, B.P., and GASQUE, P. (1999). Increased complement biosynthesis by microglia and complement activation on neurons in Huntington's disease. Exp. Neurol. 159, 362-376.
82. SOANE, L., CHO, H.J., NICULESCU, F., RUS, H., and SHIN, M.L. (2001). C5b-9 terminal complement complex protects oligodendrocytes from death by regulating Bad through phosphatidylinositol 3-kinase/Akt pathway. J. Immunol. 167, 2305-2311.
83. SOANE, L., RUS, H., NICULESCU, F., and SHIN, M.L. (1999). Inhibition of oligodendrocyte apoptosis by sublytic C5b-9 is associated with enhanced synthesis of bcl-2 and mediated by inhibition of caspase-3 activation. J. Immunol. 163, 6132-6138.
84. STAHEL, P.F., KARIYA, K., SHOHAMI, E., et al. (2000). Intracerebral complement C5a receptor (CD88), expression is regulated by TNF and lymphotoxin-alpha following closed head injury in mice. J. Neuroimmunol. 109, 164-172.
85. STAHEL, P.P., MORGANTI-KOSSMANN, M.C., and KOSSMANN, T. (1998). The role of the complement system in traumatic brain injury. Brain Res. Brain Res. Rev. 27, 243-256.
86. STAHEL, P.P., MORGANTI-KOSSMANN, M.C., PEREZ, D., et al. (2001). Intrathecal levels of complement-derived soluble membrane attack complex (sC5b-9), correlate with blood-brain barrier dysfunction in patients with traumatic brain injury. J. Neurotrauma 18, 773-781.
87. STORCH, M.K., PIDDLESDEN, S., HALTIA, M., IIVANAINEN, M., MORGAN, P., and LASSMANN, H. (1998). Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination. Ann. Neurol. 43, 465-471.
88. STREIT, W.J., SEMPLE-ROWLAND, S.L., HURLEY, S.D., MILLER, R.C., POPOVICH, P.G., and STOKES, B.T. (1998). Cytokine mRNA profiles in contused spinal cord and axotomized facial nucleus suggest a beneficial role for inflammation and gliosis. Exp. Neurol. 152, 74-87.
89. TAOKA, Y., and OKAJIMA, K. (1998). Spinal cord injury in the rat. Prog. Neurobiol. 56, 341-358.
90. TONAI, T., SHIBA, K., TAKETANI, Y., et al. (2001). A neutrophil elastase inhibitor (ONO-5046), reduces neurologic damage after spinal cord injury in rats. J. Neurochem. 78, 1064-1072.
91. TÖRNQVIST, E., LIU, L., ALDSKOGIUS, H., HOLST, H.V., and SVENSSON, M. (1996). Complement and clusterin in the injured nervous system. Neurobiol. Aging 17, 695-705.
92. VAN BEEK, J., CHAN, P., BERNAUDIN, M., PETIT, E., MACKENZIE, E.T., and FONTAINE, M. (2000). Glial responses, clusterin, and complement in permanent focal cerebral ischemia in the mouse. Glia 31, 39-50.
93. VAN DER LAAN, L.J., RUULS, S.R., WEBER, K.S., LODDER, I.J., DÖPP, E.A., and DIJKSTRA, C.D. (1996). Macrophage phagocytosis of myelin in vitro determined by flow cytometry: phagocytosis is mediated by CR3 and induces production of tumor necrosis factor-alpha and nitric oxide. J. Neuroimmunol. 70, 145-152.
94. VANGURI, P., KOSKI, C.L., SILVERMAN, B., and SHIN, M.L. (1982). Complement activation by isolated myelin: activation of the classical pathway in the absence of myelin-specific antibodies. Proc. Natl. Acad. Sci. U.S.A. 79, 3290-3294.
95. VASTHARE, U.S., BARONE, F.C., SARAU, H.M., et al. (1998). Complement depletion improves neurological function in cerebral ischemia. Brain Res. Bull. 45, 413-419.
96. WALSH, M.J., and MURRAY, J.M. (1998). Dual implication of 2′,3′-cyclic nucleotide 3′ phosphodiesterase as major autoantigen and C3 complement-binding protein in the pathogenesis of multiple sclerosis. J. Clin. Invest. 101, 1923-1931.
97. WAMIL, A.W., WAMIL, B.D., and HELLERQVIST, C.G. (1998). CM101-mediated recovery of walking ability in adult mice paralyzed by spinal cord injury. Proc. Natl. Acad. Sci. U.S.A. 95, 13188-13193.
98. WEBSTER, S., LUE, L.F., BRACHOVA, L., et al. (1997). Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease. Neurobiol. Aging 18, 415-421.
99. WREN, D.R., and NOBEL, M. (1989). Oligodendrocytes and oligodendrocyte/type-2 astrocyte progenitor cells of adults rats are specifically susceptible to the lytic effects of complement in the absence of antibody. Proc. Natl. Acad. Sci. USA 86, 9025-9029.